Abzena Appoints Louise Duffy as Senior Vice President and Head of Scientific Project Leadership - Abzena

Abzena Appoints Louise Duffy as Senior Vice President and Head of Scientific Project Leadership

14 April 2020

Abzena, the leading Partner Research Organization (PRO) for outsourced solutions integrating gene to GMP services for large molecules and bioconjugates, announced it has appointed Dr. Louise Duffy as Senior Vice President and Head of the Scientific Project Leadership.

Reporting to Kimball Hall, Chief Operating Officer, and complementing the operational and technical leadership team, Dr. Duffy will focus on scientific quality and operational timelines to ensure that integrated biologics projects for Abzena’s customers achieve successful IND or BLA outcomes.

Dr. Jonathan Goldman MD, CEO of Abzena commented, “I am delighted that Louise is joining us. She brings exceptional experience in science, leadership and partnerships that are needed to advance our growth.  Abzena delivers fully integrated gene to GMP manufacturing in biologics, complex large molecules and bioconjugation, including antibody drug conjugates under one roof.  We have shown great success in transitioning complex molecules through lead selection into clinical development in multiple therapeutic areas.  Louise’s expertise will enhance our client partner’s experience.”

Dr. Duffy has more than 30 years’ experience in the industry, including increasing responsibilities at GlaxoSmithKline and Janssen. For the last two years, as an independent consultant in biopharmaceuticals and cell and gene therapies, Dr. Duffy has developed strategic CMC plans to support regulatory filings such as INDs, IMPDs, BLA, and MAAs.

Dr. Duffy received both her Doctorate in Chemical Engineering and MSc in Advanced Chemical Engineering from Imperial College in London, UK and her BSc (Hons) in Chemistry and Biochemistry from the University of British Columbia.

About Abzena

Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com.

For more information, please contact:

info@abzena.com

Interested in our services? Get In Touch